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Abstract
 
We generated vascular cell adhesion molecule (VCAM)-1 “knock-in” mice and Cre recombi-
 
nase transgenic mice to delete the VCAM-1 gene (
 
vcam-1
 
) in whole mice, thereby overcoming
the embryonic lethality seen with conventional 
 
vcam-1
 
–deficient mice. 
 
vcam-1
 
 knock-in mice
expressed normal levels of VCAM-1 but showed loss of VCAM-1 on endothelial and hemato-
poietic cells when interbred with a “TIE2Cre” transgene. Analysis of peripheral blood from
conditional 
 
vcam-1–
 
deficient mice revealed mild leukocytosis, including elevated immature B
cell numbers. Conversely, the bone marrow (BM) had reduced immature B cell numbers, but
 
normal numbers of pro-B cells. 
 
vcam-1
 
–deficient mice also had reduced mature IgD
 
1
 
 B and T
cells in BM and a greatly reduced capacity to support short-term migration of transferred B
cells, CD4
 
1
 
 T cells, CD8
 
1
 
 T cells, and preactivated CD4
 
1
 
 T cells to the BM. Thus, we report
an until now unappreciated dominant role for VCAM-1 in lymphocyte homing to BM.
Key words: VCAM-1 • Cre recombinase • knockout mice • bone marrow • lymphocyte 
migration
 
Introduction
 
Leukocyte trafficking is a dynamic orchestration of molec-
ular cues. Numerous molecules participate in one or more
steps in an integrated multistep process of leukocyte rolling
on the blood vessel wall, followed by “activation,” firm ad-
herence, and transmigration into tissue (1–3). One of the
players in this scenario is vascular cell adhesion molecule
 
(VCAM)
 
1
 
-1, which mediates both rolling on endothelial
cells (ECs) and firm adherence (4–7). VCAM-1 was origi-
nally identified on the surface of activated human umbilical
vein ECs as a mediator of adhesion with melanoma cells
and lymphocytes (8–10). VCAM-1 expression can be in-
 
duced by numerous factors, including TNF-
 
a
 
, IL-1, IL-4,
IL-13, and intercellular adhesion molecule (ICAM)-1
cross-linking (8–14). The ability of VCAM-1 to facilitate
leukocyte adherence to ECs is thought to be a critical fac-
tor in the initiation and/or perpetuation of inflammation
and autoimmunity. Upregulated VCAM-1 expression on
ECs is associated with several diseases including multiple
sclerosis, allograft rejection, atherogenesis, rheumatoid ar-
thritis, appendicitis, dermatitis, and inflammatory bowel
disease (15–23).
Besides inducible expression on ECs, VCAM-1 is ex-
pressed on peripheral LN (PLN) and mesenteric LN
(MLN) high endothelial venules (HEVs; reference 24),
bone marrow (BM) stromal cells (25), BM microvascula-
ture (7, 26, 27), thymic epithelial cells (28), spleen stromal
cells (29, 30), and spleen red pulp macrophages and den-
 
dritic cells
 
 
 
(DCs) (31, 32). Although not normally ex-
pressed by T cells, VCAM-1 is reportedly expressed by
 
thymocytes and T cells undergoing apoptosis (33). VCAM-1
on HEVs has an apparently redundant role in lymphocyte
migration to LNs (24), whereas VCAM-1 on BM mi-
crovessels has an overlapping role with selectins in hemato-
poietic progenitor cell recruitment into the BM compart-
ment (7, 34). VCAM-1 on BM stromal cells might have a
role in B cell development. Anti–VCAM-1 antibody
greatly reduced B lymphocyte formation in long-term BM
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Abbreviations used in this paper:
 
 BM, bone marrow; CG, chicken 
 
g
 
-glob-
ulin; CMFDA, 5-chloromethylfluorescein diacetate; DC, dendritic cell;
EC, endothelial cell; ES, embryonic stem; FDC, follicular dendritic cell;
GC, germinal center; HEV, high endothelial venule; ICAM, intercellular
adhesion molecule; MLN, mesenteric LN; NP, 4-hydroxy-3-nitrophenyl;
PLN, peripheral LN; PNA, peanut agglutinin; VCAM, vascular cell adhe-
sion molecule; VLA, very late antigen. 
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cultures (25). This is seemingly in contrast to studies with
BM stromal cell clones from VCAM-1 null mice, where
long-term maintenance and proliferation of clonable pre-B
cells, cobblestone formation, and differentiation to IgM-
secreting mature B cells were equally possible on VCAM-1
 
1
 
and VCAM-1
 
2
 
 BM stromal cells (35). Studies of 
 
a
 
4
 
 inte-
grin–deficient hematopoietic progenitors in chimeric mice
revealed a defect in 
 
a
 
4
 
 integrin–deficient B cell develop-
ment at the pre-B cell stage (36), reinforcing the principle of
a role in B cell development for VCAM-1 or some other 
 
a
 
4
 
integrin receptor. That is, the heterodimeric integrins 
 
a
 
4
 
b
 
1
 
(very late antigen [VLA]-4) and 
 
a
 
4
 
b
 
7 
 
bind VCAM-1, but
VLA-4 (the principal VCAM-1 ligand) also binds fibronec-
tin and itself via homotypic aggregation (37–44).
Recent studies also suggest that VCAM-1 might be more
promiscuous than at first appreciated, in that 
 
a
 
D
 
b
 
2
 
 (ex-
pressed by a variety of leukocytes) and 
 
a
 
9
 
b
 
1
 
 (expressed by
neutrophils) also bind to VCAM-1 (45–47). Thus, VCAM-1
may have roles besides the potential roles revealed by 
 
a
 
4
 
integrin–deficient hematopoietic progenitors. Attempts by
others to further investigate the roles of VCAM-1 using ge-
netically deficient mice met with limited success because
 
vcam-1
 
 deficiency caused embryonic lethality in two inde-
pendent studies (31, 48), although a few VCAM-1 null mice
did survive embryonic lethality (31, 35). This hurdle has
been overcome here by the generation of 
 
vcam-1
 
 “knock-
in” mice and “TIE2Cre” Cre recombinase transgenic mice.
 
vcam-1
 
 knock-in mice express normal levels of VCAM-1
but allow deletion of the 
 
vcam-1
 
 gene promoter and first
exon, using the Cre recombinase/
 
loxP
 
 system. When inter-
crossed with TIE2Cre transgenes, 
 
vcam-1
 
 knock-in mice
showed virtually complete loss of VCAM-1 on ECs and he-
matopoietic cells. These semiregulated 
 
vcam-1
 
–deficient
mice had reduced immature B cells and mature lymphocytes
in BM, and a greatly reduced capacity to recruit B cells and
T cells to BM in short-term migration assays.
 
Materials and Methods
 
Generation of VCAM-1 Knock-in Mice. 
 
The VCAM-1 gene
(
 
vcam-1
 
) was isolated from a 
 
l
 
 Fix II 129/Ola library. The tar-
geted region spans a 7-kb region between an upstream BamHI
site and the 3
 
9
 
 end of the pGEM4 clone (see Fig. 1). This 3
 
9
 
 end
does not include the BamHI site, which is expected to be slightly
further downstream in 
 
vcam-1
 
 (49–51). The 7-kb targeted region
was subcloned into pBluescript II (Stratagene) as two separate
halves: an upstream BamHI-EcoRI region and a downstream
EcoRI-SalI region (using the pGEM4 SalI site at the 3
 
9
 
 end). A
HindIII fragment containing a herpes simplex virus thymidine ki-
nase (HSV-tk) gene cassette (52) was inserted into the BamHI site
of the upstream 
 
vcam-1
 
 fragment clone after Klenow end-filling.
This modified upstream 
 
vcam-1
 
 clone constituted the left arm of
the targeting construct.
The BamHI site in the downstream 
 
vcam-1
 
 clone (in the
pBluescript II polylinker) was eliminated by Klenow end-filling
and religation. A 
 
loxP
 
 site oligonucleotide duplex was designed to
incorporate a BamHI site and EcoRI overhangs, but with a true
EcoRI site only at the 5
 
9
 
 
 
end next to the BamHI site (sense
strand: 5
 
9
 
-phosphate-AATTCGGATCCATAACTTCGTAT-
 
AGCATACATTATACGAAGTTATGC; antisense strand: 5
 
9
 
-
phosphate-AATTGCATAACTTCGTATAATGTATGCTAT-
ACGAAGTTATGGATCCG). The two oligonucleotides were
annealed together and ligated into the EcoRI site of the modi-
fied downstream 
 
vcam-1
 
 clone. The reappearance of a BamHI
site was used to screen for positive clones. Clones that had the
desired 
 
loxP
 
 site orientation and correct sequence were identi-
fied by sequencing with the pBluescript II reverse primer. The
desired orientation of the 
 
loxP
 
 was that which placed the newly
introduced BamHI site and the one remaining EcoRI site at the
5
 
9
 
 end of the 
 
loxP
 
 sequence and 
 
vcam-1
 
 fragment rather than be-
tween the two.
An XhoI site was then introduced into the HindIII site in in-
tron 1 of the modified downstream 
 
vcam-1
 
 clone by partial Hind-
III digestion and ligation with an oligonucleotide duplex bearing
HindIII site overhangs and an XhoI site. Clones with an XhoI
site inserted into the desired HindIII site in intron 1 without loss
of the small HindIII intron 1 fragment (see Fig. 1) were identified
by digestion with BamHI, HindIII, XhoI, and combinations
thereof.
A 
 
loxP
 
-flanked neomycin resistance cassette was then inserted
into the newly introduced XhoI site of the modified upstream
 
vcam-1
 
 clone as an XhoI-SalI fragment from pLox2neopA (see
below). The desired orientation of the insert (see Fig. 1) was
identified by digestion with BamHI, EcoRI, XhoI, and combina-
tions thereof. This modified downstream 
 
vcam-1
 
 clone consti-
tuted the right arm of the targeting construct. The construct
pLox2neopA (Koni, P., and R. Flavell, unpublished results) con-
tains a neomycin resistance cassette from pMC1neopA (Strat-
agene) flanked by 
 
loxP
 
 sites in pBluescript II (Stratagene).
pLox2neopA was created with SalI and XhoI sites at the 5
 
9
 
 and 3
 
9
 
ends (relative to the neomycin resistance cassette), respectively (as
well as several other sites).
The left and right arms of the targeting construct were then
joined by first excising the left arm, by partial digestion with
EcoRI and then complete digestion at the pBluescript II
polylinker NotI site. The full-length 4.5-kb left arm was then in-
serted into the right arm construct between the upstream
polylinker NotI and EcoRI sites. Both the left and right arms of
the targeting construct were therefore 
 
z
 
2.7 kb in size (excluding
the 1.6-kb 
 
loxP
 
-flanked 
 
vcam-1
 
 promoter/exon 1 region). The
targeting vector was linearized at the 3
 
9 
 
SalI site and 25 
 
m
 
g was
used to electroporate 10
 
7
 
 W9.5 embryonic stem (ES) cells. ES
cells were then plated onto mitomycin C–treated primary embry-
onic fibroblasts. Double drug selection for homologous recombi-
nants was begun 24 h later with 2 
 
m
 
M gancyclovir (Syntex) and
0.3 mg/ml G418 (GIBCO BRL).
ES cell colonies and subsequent mice were screened by BamHI
digest Southern blot analysis using probes A and B (see Fig. 1).
Probe A was a 1.0-kb EcoRI-EcoRV fragment. Probe B was a
1.0-kb SphI-SalI fragment at the 3
 
9
 
 end of the genomic clone. All
probes were products of 
 
32
 
P incorporation by random priming
using [
 
32
 
P]dCTP (Amersham Pharmacia Biotech) and a Prime-It
II kit (Stratagene). Homologous recombinant ES cells were in-
jected into C57BL/6 blastocytes and chimeric males were bred to
C57BL/6 females. Heterozygous targeted mice still bearing the
neomycin resistance cassette in 
 
vcam-1
 
 intron 1 (
 
vcam
 
1
 
/neo
 
) were
thus derived from one out of four homologous recombinant ES
cell clones and were then interbred to obtain 
 
vcam-1
 
neo/neo
 
 mice
and wild-type littermates. All mice were housed in specific
pathogen-free conditions in accordance with institutional animal
care and use guidelines.
To avoid any possible interference with VCAM-1 expression, 
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the neomycin resistance cassette was then deleted to create the
 
vcam-1
 
flox
 
 allele (see Fig. 1 B for definitions). This “partial” dele-
tion was achieved by use of the 
 
splicer
 
 mouse (see below).
 
Generation of Cre Recombinase Transgenic Mice.
 
 
 
Splicer
 
 mice
were generated with a transgene from pTet-Cre, which contains
the Cre recombinase coding sequence from pBS185 (GIBCO
BRL) cloned into the EcoRV site of pTet-Splice (GIBCO BRL)
as a Klenow-blunted MluI-XhoI fragment. TIE2Cre transgenes
were generated with a TIE2 kinase promoter/enhancer cassette
described previously (53). The construct pSPTg.T2FXK (pg54)
(a gift from Thomas Sato, Beth Israel Hospital, Boston, MA) con-
tained the TIE2 kinase promoter and enhancer with HindIII and
NotI sites between the two. These sites allowed us to direction-
ally clone a HindIII-NotI fragment from pTet-Cre, thus intro-
ducing the Cre recombinase coding sequence, intronic donor/ac-
ceptor sequences, and polyadenylation signal sequences into
pg54. This TIE2Cre transgene was then excised from the vector
backbone using SalI.
All transgenic mice were generated on a (C3H 
 
3 
 
C57BL/6)F
 
2
 
background. Screening of tail DNA for Cre recombinase trans-
gene presence was by PCR with the following primers: forward,
5
 
9
 
-CGATGCAACGAGTGATGAGG-3
 
9
 
; and reverse, 5
 
9
 
-CG-
CATAACCAGTGAAACAGC-3
 
9
 
. Positive founder mouse lines
were then crossed with C57BL/6 mice for two generations be-
fore interbreeding with VCAM-1 knock-in mice.
 
Lung Challenge and Immunohistology.
 
 
 
Mice were given an in-
traperitoneal injection of alum-precipitated antigen consisting of
20 
 
m
 
g OVA (grade V; Sigma-Aldrich) adsorbed onto 2 mg alu-
minum hydroxide in 0.1 ml PBS. A booster injection was given
5 d later. Control animals received precipitated alum in PBS only.
12 d after the first sensitization, mice were challenged by expo-
sure to an aerosol of 0.5% OVA in PBS, twice for 1 h each with a
4-h interval. This was done by placing the mice in a Plexiglass
chamber attached to an ultrasonic nebulizer (1–5 
 
m
 
m particles;
DeVilbiss), with a small hole to allow continuous airflow.
Lungs were excised 2 d later, inflated with 1:3 dilution of Tis-
sue-Tek OCT Compound (VWR Scientific) in PBS, and then
frozen in OCT compound using a dry ice/methylbutane bath.
Sections were cut onto silanized glass slides at 7-
 
m
 
m thickness and
allowed to air dry for 1 h before being fixed in cold acetone for
10 min and stored at 
 
2
 
70
 
8
 
C until use.
For staining, sections were rehydrated in wash buffer (0.1 M
Tris-Cl, pH 7.4, 0.01% Triton X-100) for 10 min. Sections were
then incubated with blocking buffer (3% BSA in wash buffer) for
30 min, and with avidin/biotin blocking kit (Vector Laboratories)
for 15 min for each step. Sections were rinsed briefly in wash
buffer before incubation for 1 h with biotin-conjugated anti–
mouse VCAM-1 (MVCAM.A; BD PharMingen) diluted in 1%
BSA/wash buffer. The sections were then washed three times for
5 min in wash buffer and incubated for 40 min with an appropri-
ate dilution of streptavidin–alkaline phosphatase (Zymed Labora-
tories) in 1% BSA/wash buffer. The sections were then washed
and developed using HistoMark Red staining system (KPL),
counterstained with Meyer’s hematoxylin, and mounted using
Permount (Fisher Scientific).
 
ROSA26R Cre Reporter 
 
b
 
-Galactosidase Histology.  ROSA-
26R reporter mice (54) were purchased from The Jackson Labo-
ratory and maintained in our facility in accordance with institu-
tional animal care and use guidelines. After crossing with the
TIE2Cre transgene, progeny were genotyped by Cre recombi-
nase PCR as described earlier, and by ROSA26R PCR using
primers as described elsewhere (54). ROSA26R1 mice were
anesthetized at 6–7 wk of age with Avertin and perfused with 4%
paraformaldehyde in PBS by cardiac puncture. Various organs
were then harvested and frozen directly in Tissue-Tek OCT
compound (VWR Scientific) using a dry ice/methylbutane bath,
and stored at 2708C until cutting. Brains were fixed for a further
20 h at 48C in 4% paraformaldehyde/PBS. Brains were then
brought to 30% sucrose/0.1 M sodium phosphate, pH 7.4, at 48C
using steps of 10% sucrose for 1 h, 20% sucrose for 8 h, and fi-
nally 30% sucrose for 16 h. Finally, brains were frozen on dry ice
and stored at 2708C until cutting.
Brain sections were cut at 30-mm thickness into PBS before
staining for b-galactosidase in 24-well plates with HistoMark
X-Gal solution (KPL) at 378C for 16–20 h. The sections were
then washed in PBS and mounted onto silanized slides with
Clearmount (Zymed Laboratories). Other tissues were cut at 10-mm
thickness onto silanized slides, fixed in cold acetone for 10 min,
and then stored at 2708C until use. Slides were then stained as
above after thawing and rehydration in PBS.
Humoral Challenge and Spleen Immunohistology.  Chicken g-glob-
ulin (CG; Sigma-Aldrich) was conjugated with (4-hydroxy-3-
nitrophenyl; NP) acetyl succinimide ester (Calbiochem) in 0.1 M
sodium borate, pH 9.2, to an NP/CG molar ratio of 13:1
(NP13CG), and then dialyzed against PBS. Mice 6–8 wk of age
were then challenged intraperitoneally with 50 mg of NP13CG
adsorbed to alum in 0.1 ml PBS. Spleens were harvested at day
10 after the challenge, frozen in Tissue-Tek OCT compound us-
ing a dry ice/methylbutane bath, and stored at 2708C until cut-
ting. Sections of 7-mm thickness were cut onto silanized glass
slides, fixed in cold acetone for 10 min, air dried, and then stored
at 2708C until use. For staining, sections were thawed for 30
min and then rehydrated in PBS for 20 min. Endogenous perox-
idase was quenched with 0.3% hydrogen peroxide for 5 min.
Sections were washed in PBS for 10 min and then preblocked
with PBS/3% BSA/0.1% Tween 20 for 30 min in a humidified
chamber. Staining for IgD was with rat anti-IgD (11–26) (South-
ern Biotechnology Associates, Inc.) and then horseradish peroxi-
dase–conjugated polyclonal goat anti-rat IgG (Southern Biotech-
nology Associates, Inc.). Germinal centers were stained with
biotin-conjugated peanut agglutinin (PNA) (EY Labs; reference
55). The presence of VCAM-1 was assessed with anti–VCAM-1
(M/K-2, rat IgG1, k)-biotin (Southern Biotechnology Associ-
ates, Inc.). Anti-CD8b.2 (53-5.8, rat IgG1, k)-biotin was used as
a negative control for VCAM-1 staining. All biotin conjugates
employed a secondary step of alkaline phosphatase–conjugated
streptavidin (Zymed Laboratories). Incubations were in a humid-
ified chamber for 1 h. Washes between steps were with PBS/
0.1% Tween 20. Substrates for horseradish peroxidase and alka-
line phosphatase were diaminobenzidine (Zymed Laboratories)
and NBT/BCIP (Zymed Laboratories). Mounting was with
Clearmount (Zymed Laboratories).
Spleen Collagenase Digestion.  Spleens were harvested into 2
ml digest buffer in a 35-mm dish on ice. Digest buffer was cal-
cium-free HBSS with 1% FCS, 2 mM L-glutamine, 0.5 mg/ml
collagenase type IV (Sigma-Aldrich), and 0.1 mg/ml deoxyribo-
nuclease type I (Sigma-Aldrich). Spleens were diced with 23-
gauge needles before incubation at 378C for 30 min. The cell sus-
pension was further disrupted by pipetting before being made up
to 10 ml with PBS/5 mM EDTA. Splenocytes were then centri-
fuged at 1,000 rpm for 5 min and resuspended into 2 ml ACK
erythroid cell lysis buffer (BioWhittaker). 1 min later, the suspen-
sion was again made to 10 ml with PBS/5 mM EDTA and re-
centrifuged. Finally, cells were resuspended in PBS/1% FCS and
filtered through 0.1-mm nylon mesh (Millipore).
Fluorocytometry.  For fluorocytometry of DCs, cells were pre-744 VCAM-1 Mediates Recirculation to Bone Marrow
pared from spleen by collagenase digestion as described above.
Otherwise, cells were recovered into 5 ml PBS/1% FCS from thy-
mus, Peyer’s patches, spleen, and/or LNs by using the plunger of a
syringe to tease the tissue between two pieces of 0.1-mm nylon
mesh (Millipore). Total BM was collected from femurs and tibias.
Splenocytes were further treated by centrifugation at 1,000 rpm for
5 min, resuspension into 2 ml ACK erythroid cell lysis buffer (Bio-
Whittaker), and then addition of 10 ml PBS 1 min later. All cell
suspensions were then centrifuged at 1,000 rpm for 5 min. Finally,
cells were resuspended into PBS/1% FCS and filtered through 0.1-
mm nylon mesh. BM was not subjected to erythroid cell lysis, but
total nucleated cell numbers in both BM and EDTA-treated blood
were determined by counting in Turk’s solution (0.01% wt/vol
gentian violet in 3% vol/vol glacial acetic acid).
Aliquots of 106 nucleated cells were made into 0.2 ml PBS/1%
FCS supplemented with 5 mg/ml FcBlock (BD PharMingen). Sam-
ples were left on ice for 30 min before primary antibodies were added
and left on ice in the dark for another 1 h. Samples were washed by
the addition of 1 ml PBS/1% FCS and centrifugation at 1,000 rpm,
48C for 5 min. Secondary antibody incubation and washing were as
above. Four-color fluorocytometry employed a FACSCalibur™ with
argon and red diode lasers (Becton Dickinson). Fluorocytometry of
spleen DCs, BM cells, and 5-chloromethylfluorescein diacetate (CM-
FDA)-labeled cells (see below) was done by counting 250,000 events.
Otherwise, 50,000 events were collected.
Anti–mouse IgM (donkey polyclonal)-Cy5 and antidigoxin
(mouse IgG polyclonal)-Cy5 were from Jackson ImmunoRe-
search Laboratories. Anti-IgD (11-26c.2a)-digoxigenin was made
and employed by us as described previously (56). All other re-
agents were from BD PharMingen.
In Vivo Lymphocyte Homing Assay.  C57BL/6J and tcra2/2
mice were purchased from The Jackson Laboratory and breeding
colonies were maintained in our animal facility according to in-
stitutional animal care and use guidelines. Cells to be labeled
were either LN (axillary, brachial, inguinal, and mesenteric) cells
from C57BL/6J mice, splenocytes from tcra2/2 mice (after ery-
throid cell lysis and washing as described earlier), or preactivated
T cells. The latter were prepared by culturing LN and spleen cells
from C57BL/6J mice (after erythroid cell lysis and washing as de-
scribed above) for 3 d at 5 3 106 cells/ml in DMEM supple-
mented with 2 mM glutamine, 50 mM 2-mercaptoethanol, 100
IU/ml penicillin, 0.1 mg/ml streptomycin, 5% FCS, 1 mg/ml
anti-CD3 antibody (clone 2C11; Southern Biotechnology Asso-
ciates, Inc.), and 50 U/ml IL-2. Cells were then washed and
rested for a further 3 d in the same medium but without anti-
CD3 antibody. Finally, dead cells were removed by centrifuga-
tion through lymphocyte separation medium (BioWhittaker).
Cells were labeled with 1 mM CMFDA succinimidyl ester
(Molecular Probes) in PBS/0.1% BSA for 5 min at 378C, and
then washed three times with PBS by centrifugation at 1,000 rpm
for 5–10 min. Finally, labeled cells were made to 2 3 108/ml in
PBS and each 8–10-wk-old recipient was given 0.1 ml intrave-
nously. 2 h later, peripheral blood, spleen, PLNs (axillary, bra-
chial, and inguinal LNs), MLNs, and BM (femurs and tibias)
were harvested for fluorocytometry as described above, with
250,000 events being counted per sample.
Figure 1. Targeting strategy and conditional deletion of the vcam-1flox allele. (A) VCAM-1 knock-in mice (bottom locus map) contain Cre recombinase
sites of recombination (loxP sites; black arrowheads). The vcam-1 coding sequence exons are depicted as striped bars, with the 59 untranslated region as a
white bar. Probes A and B are shown above the top map line as black bars. Endonuclease sites shown are BamHI (B), EcoRI (R), HindIII (H), SphI (S), and
XhoI (X). (B) The vcam-1neo allele (neo) is shown along with two of the possible outcomes of Cre recombinase–mediated deletion, the vcam-1flox allele (flox)
and the vcam-1D allele (D). (C and D) BamHI Southern blot analysis of tail DNA using probes A and B, respectively. Deletion of the vcam-1neo allele to gen-
erate the vcam-1flox allele (flox) and the vcam-1D allele (D) in whole mice was achieved by interbreeding with the splicer transgene. (E) Southern blot analysis of
mouse tail DNA as in D. A vcam-1flox/D mouse (track 1) is shown alongside two TIE2Cre1 mice born of vcam-1flox/flox parents, but with the TIE2Cre1 parent
being the father (track 2) or mother (tracks 1 and 3). (F and G) Southern blot analysis as in D of genomic DNA from a vcam-1flox/flox/TIE2Cre1 mouse and a
vcam-1flox/D/TIE2Cre1 mouse, respectively. Tissues analyzed were: BM; Br, brain (cortex); H, heart; Ki, kidney; Li, liver; Lu, lung; LNs; M, muscle (thigh);
Pa, pancreas; and Sp, spleen.745 Koni et al.
Results
Generation of Conditional vcam-1–deficient Mice.  Mice
bearing Cre recombinase loxP sites of recombination were
generated by homologous recombination in 129/Ola ES
cells using conventional techniques (Fig. 1). The vcam-1 re-
gion flanked by loxP sites includes the defined cytokine-
responsive promoter region (49) and exon 1, with the
loxP-flanked neomycin resistance cassette in intron 1. Exon
1 contains the signal peptide sequence and is critical to all
the alternatively spliced forms of vcam-1 (49–51). This re-
gion of vcam-1 was previously deleted in mice using con-
ventional techniques and resulted in embryonic lethality, as
described by others (31, 48). Thus, the targeting strategy
employed here was believed to be appropriate for achiev-
ing vcam-1 inactivation, once the loxP-flanked region is de-
leted. The neomycin resistance cassette was removed by
use of the splicer mouse (see Materials and Methods) to
avoid any possible interference of VCAM-1 expression.
Indeed,  vcam-1neo/neo mice had four- to fivefold lower
VCAM-1 on spleen DCs compared with vcam-1flox/flox mice
and C57BL/6J mice (data not shown).
Conditional deletion of the vcam-1flox allele (see Fig. 1 B
for definitions) was achieved with a TIE2Cre Cre recombi-
nase transgene. The latter was generated with the TIE2 ki-
nase promoter/enhancer expression cassette, which gives
uniform expression in all ECs during both embryogenesis
and adulthood (53). When both parents had a vcam-1flox/flox
genotype and the TIE2Cre1 parent was a female, all of the
progeny had a vcam-1flox/D genotype regardless of whether
or not they themselves were TIE2Cre1 (Fig. 1 E). Thus,
the TIE2Cre transgene appeared to delete the vcam-1flox al-
lele in the germline of the mother.
Both  vcam-1flox/flox/TIE2Cre1 mice (born with the
TIE2Cre1 parent being the father) and vcam-1flox/D/
TIE2Cre1 mice had extensive deletion of the vcam-1flox al-
lele in several tissues, but especially in tissues rich in he-
matopoietic cells (Fig. 1, F and G). This was anticipated
because de novo TIE2 kinase is expressed by hematopoietic
progenitors and ECs (57, 58). Virtually 100% deletion was
seen in the BM of vcam-1flox/D/TIE2Cre1 mice (Fig. 1 G).
The high degree of deletion in lung tissue of vcam-
1flox/flox/TIE2Cre1 mice was reflected by a complete lack of
VCAM-1 on lung ECs of vcam-1flox/flox/TIE2Cre1 mice af-
ter OVA sensitization and aerosol challenge, which upreg-
ulates VCAM-1 expression in the lung (Fig. 2 A). VCAM-1
expression was also examined on BM myeloid lineage cells,
spleen myeloid DCs, and spleen lymphoid DCs by fluoro-
cytometry. This revealed relatively normal levels of
VCAM-1 in vcam-1flox/flox mice (Fig. 2 B), whereas vcam-
1neo/neo mice had four- to fivefold lower VCAM-1 (data not
shown). VCAM-1 levels were greatly reduced in vcam-
1flox/flox/TIE2Cre1 mice, but complete deletion was
achieved only in vcam-1flox/D/TIE2Cre1 mice (Fig. 2 B). As
illustrated below (see Fig. 6), VCAM-1 was also deleted
from spleen red pulp macrophages.
Finally, ROSA26R mice (54) were employed to further
visualize deletion by the TIE2Cre transgene. ROSA26R
mice express b-galactosidase only after Cre recombinase–
mediated deletion of a “STOP” signal, and thus allow a
histological evaluation of sites of Cre recombinase activity
by staining for b-galactosidase activity (54). Thus, male
TIE2Cre1 mice were crossed with ROSA26R mice (54)
to obtain double-positive and ROSA26R1/TIE2Cre2
progeny. Double-positive mice clearly revealed Cre re-
combinase activity as blue staining in the ECs of brain, kid-
Figure 2. Cre recombinase–mediated deletion in ECs and hematopoi-
etic cells. (A) Lung sections are shown for a vcam-11/1 mouse (WT) and a
vcam-1flox/flox/TIE2Cre1 mouse (KO) after OVA sensitization and aerosol
challenge. A representative blood vessel is shown in each panel (arrow);
original magnification: 3500. VCAM-1 staining is seen on ECs of the
vcam-11/1 mouse lung (red) but not on ECs of the vcam-1flox/flox/
TIE2Cre1 mouse lung. (B) VCAM-1 (open histograms) was assessed on
BM B2202 myeloid lineage cells (i.e., excluding high side-scatter granu-
loid cells and low forward-scatter erythroid cells, spleen CD11c1CD8a2
myeloid DCs, and spleen CD11c1CD8a1 lymphoid DCs by fluorocy-
tometry. Anti-CD8b.2 (clone 53-5.8) was used as an isotype control
(shaded histograms). The small peak of CD8b.21 cells among
CD11c1CD8a1 splenocytes is expected, since it is known that a small
fraction of CD81 T cells are CD11c1.746 VCAM-1 Mediates Recirculation to Bone Marrow
ney, LNs, spleen, and thymus (Fig. 3), while no staining
was seen in ROSA26R1/TIE2Cre2 mice (data not
shown). The blue staining of capillaries seen in the brain
and thymus sections was typical. The intense blue staining
of HEVs in the axillary LNs shown was typical of HEVs,
and was also representative of thymic LNs and MLNs (data
not shown). The relatively high staining intensity seen with
HEV cells is presumably a reflection of the degree of
b-galactosidase expression driven by the ROSA26R re-
porter promoter. It is not a reflection of more or less Cre
recombinase–mediated deletion of the ROSA26R reporter
allele because there is only one ROSA26R allele per cell.
The completeness of deletion among HEV cells is wit-
nessed at least by the blue coloration of the entire circum-
ference of HEVs in every example seen. There was also
consistent staining of arterioles and larger vessels in spleen
sections and uniform staining of B cell follicles, in agree-
ment with the earlier observation of complete deletion of
the vcam-1flox allele in hematopoietic cells. The apparent lack
of staining in T cell areas of LNs and spleen as well as the
thymus medulla may be due to the fact that T cells have a
b-galactosidase inhibitory activity, as noted by others (59).
Altered Lymphocyte Populations in Peripheral Blood and the
BM Compartment. Fluorocytometry of cells from thymus,
spleen, MLNs, PLNs (axillary, brachial, and inguinal), and
Peyer’s patches of vcam-1flox/flox and vcam-1flox/D/TIE2Cre1
mice did not reveal any significant differences in leukocyte
types or absolute numbers (data not shown). However,
analysis of peripheral blood revealed mild leukocytosis in
vcam-1flox/D/TIE2Cre1 mice, including elevated levels of
B2201IgDloIgMhi immature B cells (Fig. 4). Peripheral
blood granuloid cells were also elevated in vcam-1flox/D/
TIE2Cre1 mice compared with their vcam-1flox/D/TIE2Cre2
littermates, although this was not statistically significant
compared with the age- and sex-matched vcam-1flox/flox mice.
Examination of BM from vcam-1flox/D/TIE2Cre1 mice
revealed a significant reduction in IgDloIgMhi immature B
cells (Fig. 5). However, there was no significant difference
in numbers of B2201CD431 pro-B cells (60), which repre-
sented z5% of total nucleated BM cells in both vcam-
1flox/flox mice and vcam-1flox/D/TIE2Cre1 mice (Fig. 5). IgD1
B cells and CD81 T cells were also reduced compared with
vcam-1flox/flox mice, with a small but statistically insignificant
reduction in total B2201 B cells and CD41 T cells (Fig. 5).
Total nucleated BM cell numbers were very similar in the
Figure 3. The TIE2Cre transgene activates the ROSA26R reporter al-
lele and results in b-galactosidase activity in brain (Br), kidney (Ki), liver
(Li), axillary LNs (LN), spleen (Sp), and thymus (Th), revealed by blue
X-Gal staining (original magnification: 3100). Brain sections were 30
mm thick while all others were 10 mm. By way of example, thick and
thin arrows in the spleen section indicate some larger vessels and arteri-
oles, respectively.
Figure 4. Peripheral blood analysis reveals leukocytosis in vcam-1flox/D/
TIE2Cre1 mice. A representative experiment (n 5 5 per group) with
age- and sex-matched vcam-1flox/flox mice (black bars), vcam-1flox/D/
TIE2Cre2 mice (striped bars), and their vcam-1flox/D/TIE2Cre1 littermates
(white bars). Total leukocyte numbers were determined from EDTA-
treated blood in Turk’s solution and are shown in millions of cells per
milliliter of blood. Differential counts were established by fluorocytome-
try. PMNs were defined on the basis of high side-scatter, with the other
cells defined as mononuclear (mono). The numbers of CD41 T cells, Ig-
DloIgMhi immature B cells, and IgD1 B cells shown on the right are not
in addition to the mononuclear cell counts but are part of the latter. Sig-
nificant differences between vcam-1flox/flox mice and vcam-1flox/D/TIE2Cre1
mice are indicated (Student’s t test, *P , 0.05; **P , 0.01).747 Koni et al.
above typical experiment, at 4.15 6 0.52 3 107 cells and
4.14 6 0.72 3 107 cells in vcam-1flox/flox mice and vcam-
1flox/D/TIE2Cre1 mice (n 5 4 mice per group), respec-
tively. The combined reduction of lymphocyte numbers
seen in vcam-1flox/D/TIE2Cre1 mice amounted to z0.3 3
107 BM cells per mouse, and was therefore less than the
standard deviation of the total nucleated BM cell numbers.
The apparently reduced levels of CD81 T cells in BM
were not obviously because of a selective loss of
CD44hiCD62Llo memory cells, CD44hiCD62Lhi “preacti-
vated/experienced” cells, or CD44loCD62Lhi naive cells. In
both vcam-1flox/flox mice and vcam-1flox/D/TIE2Cre1 mice, na-
ive cells represented approximately one third of BM CD81
T cells (data not shown). On the other hand, the small but
statistically insignificant reduction in BM CD41 T cells also
revealed a significant reduction in the naive fraction of these
cells. That is, naive CD41 T cells represented 10.6 6 4.0
and 5.2 6 2.9% of total BM CD41 T cells in vcam-1flox/flox
mice and vcam-1flox/D/TIE2Cre1 mice, respectively (Stu-
dent’s  t test, P , 0.05). This translated to absolute numbers
of BM naive CD41 T cells in the above typical experiment
(n 5 4 mice per group) of 3,282 6 1,597 and 1,240 6 729
cells in vcam-1flox/flox mice and vcam-1flox/D/TIE2Cre1 mice,
respectively (Student’s t test, P , 0.05).
Normal Humoral Responses in Conditional vcam-1–deficient
Mice.  Despite the reduced frequency of immature B cells
in the BM of vcam-1flox/D/TIE2Cre1 mice and their increased
numbers in peripheral blood, vcam-1flox/D/TIE2Cre1 mice
showed relatively normal spleen B cell follicles with robust
germinal center (GC) formation upon intraperitoneal chal-
lenge with NP13CG adsorbed to alum (Fig. 6). There was
also no significant difference in anti-NP IgG1 levels in the
serum of vcam-1flox/flox mice (n 5 4) versus vcam-1flox/D/
TIE2Cre1 mice (n 5 8) at days 10 and 35 after challenge
(data not shown). Finally, the latter mice were given a
booster injection of 0.2 mg soluble NP13CG in PBS at day
35 after the challenge and serum anti-NP IgG1 was deter-
mined 6 d later. A significant difference was not seen be-
tween the two groups of mice (data not shown).
Of note is the fact that vcam-1flox/D/TIE2Cre1 mice still
had VCAM-1 on follicular dendritic cells (FDCs) (Fig. 6).
Also, VCAM-1 was not completely absent from the spleen
red pulp compared with the negative staining by the anti-
CD8b control (Fig. 6), presumably a result of VCAM-1
expression by spleen stromal cells (29, 30).
Impaired Lymphocyte Migration to BM.  Having observed
reduced lymphocyte numbers in BM, short-term migration
assays were performed with CMFDA-labeled lymphocytes
from LNs of C57BL/6J donor mice. The absolute numbers
of CMFDA-labeled cells recovered from the spleens of
vcam-1flox/flox recipients versus vcam-1flox/D/TIE2Cre1 recipi-
ents were not significantly different (data not shown). The
fractions of CMFDA-labeled cells recovered in spleen,
MLNs, and PLNs were also similar in the two groups of
mice, but vcam-1flox/D/TIE2Cre1 mice clearly had greatly
reduced CMFDA-labeled cells in BM (Fig. 7). Short-term
migration of IgD1, CD41, and CD81 cells to the BM
compartment of vcam-1flox/D/TIE2Cre1 recipients was re-
duced on average by z93, 74, and 77% compared with the
vcam-1flox/flox recipients, respectively. The actual frequencies
of CMFDA-labeled IgD1 cells among total nucleated BM
cells in vcam-1flox/flox recipients and vcam-1flox/D/TIE2Cre1
recipients were 0.118 6 0.022 and 0.008 6 0.002%, re-
spectively.
Short-term migration assays were also performed with
CMFDA-labeled splenocytes from tcra2/2 donors, revealing
that the reduced short-term migration to BM by IgD1 B
cells was also true of other B cell subsets (Fig. 8). This re-
duced short-term migration to BM was reflected in elevated
cell numbers in peripheral blood (Fig. 8). The exact identity
of the cells among the IgDloIgMhi subset that had either
homed to BM or remained in peripheral blood was not de-
termined, but these cells might have included marginal zone
memory B cells and/or immature “transitional” B cells.
To further dissect the requirement for VCAM-1 in
CD41 T cell migration, short-term migration assays were
then performed with preactivated/experienced T cells (Fig.
9). This revealed greatly impaired short-term migration to
BM of vcam-1flox/D/TIE2Cre1 mice by both CD41CD62Lhi
T cells and CD41CD62Llo T cells (75 and 70% reduction,
respectively). The absolute numbers of CMFDA-labeled
cells in spleen and PLNs mirrored the earlier results, with
no apparent difference (Fig. 9). Also, as might be expected,
CD41CD62Lhi cells preferentially homed to PLNs com-
pared with CD41CD62Llo cells (Fig. 9).
Figure 5. Reduced lymphocytes in BM of vcam-1flox/D/TIE2Cre1 mice.
(A) Representative IgD versus IgM profile of B2201 cells in the BM of a
vcam-1flox/flox mouse and a vcam-1flox/D/TIE2Cre1 mouse showing reduced
IgDloIgMhi immature B cells and IgD1 B cells in the latter. (B and C) Abso-
lute lymphocyte numbers in the BM of age- and sex-matched vcam-1flox/flox
mice (black bars) and vcam-1flox/D/TIE2Cre1 mice (white bars), showing
normal B2201CD431 pro-B cell numbers but reduced numbers of other
lymphocyte types. Significant differences between the two groups (n 5 4
each) are indicated (Student’s t test, *P , 0.02; **P , 0.01; ***P , 0.002).748 VCAM-1 Mediates Recirculation to Bone Marrow
Discussion
We have employed the Cre recombinase/loxP system to
generate  vcam-1 knock-in (vcam-1flox/flox) mice. We also
generated a Cre recombinase transgene (TIE2Cre) to de-
lete this conditional vcam-1 allele in whole mice. Analysis
of sites of TIE2Cre activity with the ROSA26R reporter
strain (54) showed the TIE2Cre transgene to be capable of
mediating deletion in ECs of at least brain, kidney, LNs,
spleen, and thymus. The b-galactosidase staining of HEV
in LNs, for example, revealed TIE2Cre-mediated deletion
in every single HEV cell (Fig. 3), suggesting 100% penetra-
tion by the transgene. Furthermore, virtually complete loss
of VCAM-1 was seen on lung ECs, BM myeloid cells,
spleen myeloid DCs, and spleen lymphoid DCs of vcam-
1flox/D/TIE2Cre1 mice. The apparent absence of VCAM-1
cannot be explained as being a result of loss of only the
anti–VCAM-1 antibody epitope (rather than VCAM-1 per
se), because the deletion strategy employed does not re-
move any of the exons encoding the mature VCAM-1
Figure 6. Relatively normal B cell re-
sponses in vcam-1flox/D/TIE2Cre1 mice. Se-
rial spleen sections from a vcam-1flox/flox
mouse (WT) and a vcam-1flox/D/TIE2Cre1
mouse (KO) 10 d after intraperitoneal chal-
lenge with NP13CG adsorbed to alum (orig-
inal magnifications: 3100). All sections
were stained with anti-IgD antibody (seen
in brown) and either PNA, anti-CD8b, or
anti–VCAM-1. PNA, CD8b, and VCAM-1
staining are in purple. Arrows in the KO
section indicate typical VCAM-1 staining
on FDCs within GCs.
Figure 7. Reduced short-
term lymphocyte migration to
BM in vcam-1flox/D/TIE2Cre1
mice. A representative experi-
ment with age- and sex-
matched  vcam-1flox/flox recipients
(black bars) and vcam-1flox/D/
TIE2Cre1 recipients (white
bars). The frequency of CM-
FDA-labeled cells (IgD1,
CD41, and CD8a1) was used to
determine the absolute num-
bers of each type of CMFDA-
labeled cell in each lymphoid
organ. These data were then represented as the percentage of homed cells, where 100% is the total number of recovered CMFDA-labeled cells in
each individual mouse (n 5 3 per group). *Significantly different from controls (Student’s t test, P , 0.02). The slightly elevated migration to PLNs
of vcam-1flox/D/TIE2Cre1 recipients was not statistically significant.749 Koni et al.
polypeptide. Rather, we have deleted the VCAM-1 pro-
moter region and exon 1. The latter contains the signal
peptide sequence and is critical to all of the alternatively
spliced forms of vcam-1 (49–51).
Our studies reveal a dominant role for VCAM-1 in lym-
phocyte migration to BM. Having said this, we have not
yet definitively demonstrated that VCAM-1 is actually ab-
sent from BM ECs in vcam-1flox/D/TIE2Cre1 mice. Al-
though we observed virtually 100% deletion of the vcam-
1flox allele in BM (Fig. 1 G), the vast majority of the BM
genomic content is undoubtedly derived from hematopoi-
etic cells. This issue will be addressed by the generation of
BM EC lines as well as BM stromal cell lines. Nonetheless,
short-term migration of B cells, CD41 T cells, and CD81
T cells to the BM of vcam-1flox/D/TIE2Cre1 mice was re-
duced on average by z80, 74, and 77%, respectively. Also,
short-term migration by CD41CD62Lhi and CD41
CD62Llo preactivated/experienced T cells was reduced on
average by z75 and 70%, respectively.
It is conceivable that the low levels of lymphocytes still
found in the BM of vcam-1flox/D/TIE2Cre1 mice are a result
of alternate or complimentary mechanisms of migration.
Certainly, this would not be unprecedented. For example,
ICAM-1–deficient mice show reduced but substantial con-
tact hypersensitivity and neutrophil migration (61, 62).
Likewise, LFA-1–deficient lymphocytes show reduced but
not absent lymphocyte migration to PLNs, MLNs, and
Peyer’s patches (24, 63). Also, P/E-selectin double defi-
ciency reduces hematopoietic progenitor cell rolling at BM
microvessels to 30–40% of control levels (7). This selectin-
independent rolling is further reduced z70% by anti–
VCAM-1 antibody, while anti–VCAM-1 antibody treat-
ment of wild-type BM microvessels reduces hematopoietic
progenitor cell rolling by only z30% (7). Finally, anti–
VCAM-1–antibody greatly reduces the migration of LFA-
1–deficient lymphocytes to BM (24). We have shown that
greatly reduced migration can also be achieved with
VCAM-1 deficiency alone, and that this applies to all three
major lymphocyte subsets. Taken together, these observa-
tions suggest that both LFA-1 receptors and VCAM-1 are
involved in lymphocyte migration to BM, but that
VCAM-1 plays a dominant role.
We have not yet definitively determined whether or not
VCAM-1 is deleted from BM stromal cells of vcam-1flox/D/
TIE2Cre1 mice. This is currently the subject of further in-
vestigation by the generation of BM stromal cell lines. This
is of potential interest because VCAM-1 on BM stromal
cells might prove to have a role in B cell development and/
or humoral response beyond those that have been revealed
by our vcam-1flox/D/TIE2Cre1 mice. For example, a4 inte-
grin–deficient hematopoietic progenitor cell chimeric mice
had greatly reduced levels of a4 integrin–deficient pre-B
cells (36), and it has not yet been determined whether the
a4 integrin receptor involved in pre-B cell development is
VCAM-1, fibronectin, or both. Also, anti–VCAM-1 anti-
body greatly reduced B lymphocyte formation in long-
term bone marrow cultures (25). However, this is in con-
trast to studies with BM stromal cell clones from VCAM-1
Figure 8. Impaired B cell re-
circulation to BM results in ele-
vated peripheral blood levels.
Age- and sex-matched vcam-
1flox/flox recipients (black bars)
and vcam-1flox/D/TIE2Cre1 re-
cipients (white bars) received
CMFDA-labeled splenocytes
from  tcra2/2 donors, and recipi-
ent lymphoid organs and blood
were harvested 2 h later (n 5 4
per group). The IgD versus IgM
profile of CMFDA-labeled cells
was determined as in the legend
to Fig. 5 A, and the frequency of CMFDA-labeled cells was used to determine the absolute numbers of each type of CMFDA-labeled cell in each
lymphoid organ. Significant differences are indicated (Student’s t test, *P , 0.01; **P , 0.005; ***P , 0.001).
Figure 9. Reduced short-
term migration by preactivated
CD41 T cells. Age- and sex-
matched vcam-1flox/flox recipients
(black bars) and vcam-1flox/D/
TIE2Cre1 recipients (white
bars) received CMFDA-labeled
preactivated/experienced T cells
as described in Materials and
Methods, and recipient lym-
phoid organs and blood were
harvested 2 h later (n 5 4 per
group). The CD4 versus
CD62L profile of CMFDA-
labeled cells was determined by fluorocytometry, and the frequency of CMFDA-labeled cells was used to determine the absolute numbers of each
type of CMFDA-labeled cell in each lymphoid organ (note the differences in scale). Significant differences are indicated (Student’s t test, *P , 0.002).750 VCAM-1 Mediates Recirculation to Bone Marrow
null mice where long-term maintenance and proliferation
of clonable pre-B cells, cobblestone formation, and differ-
entiation to IgM-secreting mature B cells were equally pos-
sible on VCAM-11 and VCAM-12 stromal cells (35).
In this issue, Leuker et al. (64) have also generated con-
ditional vcam-1–deficient mice using an IFN-inducible Cre
recombinase system. These authors show that their vcam-1–
deficient mice have a phenotype similar to our mice. In
addition, they show relatively low antigen-specific serum
antibody several weeks after challenge, after secondary
challenge (64). We did not find reduced humoral responses
in our mice (data not shown), perhaps due to differences in
humoral challenge. Having said this, we anticipate that this
difference in humoral response will be determined to be
because of the nature of our respective conditional
VCAM-1 deletion strategies. That is, the IFN-induced
vcam-1–deficient mice of Leuker et al. might lack VCAM-1
on cells that our mice do not (e.g., FDCs, spleen stromal
cells, and/or BM stromal cells). First, in vitro studies sug-
gest that VCAM-1 on FDCs participates in adherence
with, and prevents apoptosis of, GC B cells (65). Second,
human spleen-derived stromal cells promote B cell blast
differentiation and survival resulting in enhanced antibody
secretion, in a manner that can be partly blocked by anti–
VCAM-1 antibody (66). Third, BM fibroblasts can rescue
cells from apoptosis (67), conceivably in a VCAM-1–depen-
dent manner. As mentioned below, plasma cells are known
to express the VCAM-1 ligand, VLA-4. Thus, antibody-
secreting cell differentiation and/or longevity might be
perturbed in mice lacking VCAM-1 on spleen and/or BM
stromal cells.
Humoral responses in our mice are being further investi-
gated, but clearly any difference between our mice and
those of Leuker et al. (64) is not because of a lack of deletion
of VCAM-1 on conventional DCs in our mice (Fig. 2 B).
In conclusion, we have generated conditional vcam-1–
deficient mice and found them to have a reduced capacity
to recruit lymphocytes to BM. Our short-term lymphocyte
homing studies showed that migration to wild-type mouse
BM (femur and tibia) represents z3–5% of the total homed
cells among the organs examined. Given that this represents
only BM from femur and tibia, the total migration to BM
probably represents a substantial fraction comparable in size
to that seen in MLNs and PLNs. As suggested by others
(24), perhaps BM should be considered as a major part of
the lymphocyte recirculation network. Besides being a
home for antibody secreting cells, the physiological rele-
vance of lymphocyte recirculation to BM is not fully un-
derstood. The BM compartment is capable of functioning
as a site of primary immune function under conditions of
disrupted lymphocyte trafficking to spleen and LNs (68). It
remains to be seen whether or not the BM compartment
can act as a priming site in other physiological conditions.
The pathophysiology of lymphocytes in BM, however, is
perhaps better appreciated. BM is a major site of involve-
ment in B and T cell malignancy (69), and metastasis to
BM by lymphomas is often a very poor prognostic indica-
tor. Both normal human plasma cells and myelomas express
VLA-4 (70), and myelomas home to the BM where they
induce massive osteoclastic bone destruction (71, 72).
Anti–VCAM-1 antibody also greatly suppresses myeloma
cell adhesion to BM ECs in vitro (73). Furthermore, direct
cell–cell contact between myeloma cells and BM stromal
cells via VCAM-1/VLA-4 is critical in some models to the
production of destructive bone resorption (74). Finally, the
most common symptoms in childhood acute leukemia, for
example, are fever, infection, and bleeding resulting from
neutropenia, anemia, and thrombocytopenia, which are
secondary consequences of BM infiltration by leukemic
cells (69). Thus, it might be beneficial to be able to prevent
such cells from homing to and/or flourishing in the BM
compartment.
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